Global /Japan /Healthcare /Drug Manufacturers - General /4893

Noile-Immune Biotech Inc.

4893

• TSE: 4893 • Delayed

152JPY 1.3%

0.9485 USD

As of 9 June 2026, Noile-Immune Biotech Inc. has a market cap of $40.52M USD, ranking #32054 globally and #3017 in Japan. It ranks #2894 in the Healthcare sector, and #1005 in the Drug Manufacturers - General industry.

Global Rank

32054

Country Rank

3017

Sector Rank

2894

Industry Rank

1005

Key Stats

Market Cap

$40.52MUSD

6.5B JPY

Enterprise Value

$16.08MUSD

2.58B JPY

Revenue (TTM)

$31.19KUSD

5.0M JPY

Net Income (TTM)

-$4.95MUSD

-793.0M JPY

PS Ratio

1299.1

PB Ratio

1.7

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Koji Tamada open_in_new

Employees

Founded

2015

Website

noile-immune.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.3%	-2.6%	-0.7%	3.4%	-8%	13%	3.4%	-82%	-82%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4893 ノイルイミューン・バイオテック株式会社 ISIN: JP3759560000 Shares Out.: Shares Outstanding: 43.277M¹ Shares Float: 16.874M² TV: TradingView: TSE: 4893 SA: Stock Analysis: TYO: 4893 YF: Yahoo Finance: 4893.T GF: Google Finance: TYO: 4893 BA: Barron's: 4893 MS: Morningstar: XTKS: 4893	152 JPY	TV: TradingView: TSE: 4893 SA: Stock Analysis: TYO: 4893 YF: Yahoo Finance: 4893.T GF: Google Finance: TYO: 4893 BA: Barron's: 4893 MS: Morningstar: XTKS: 4893

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.51B 13.07T JPY 201K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.12B 8.36T JPY 129K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.77B 5.9T JPY 91K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.32B 4.86T JPY 75K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.77B 4.13T JPY 64K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.88B 2.71T JPY 42K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 890K%	97.4	United States
Roche Holding AG SIX: RO	$322.98B 256.25B CHF 797K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.68B 215.59B GBP 712K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$275.9B 218.9B CHF 681K%	20.5	Switzerland

chevron_leftBack